PharmAust kick-starts MND trial with lead drug and reports positive signs in canine cancer trials
Clinical stage biotechnology company PharmAust's (ASX: PAA) September quarter was highlighted by the commencement of its Motor Neurone Disease (MND) trial, recruiting its first four patients, as additional patients undergo screening to become the next-in-line.
Source: smallcaps.com.au
